Comparative Pharmacology
Head-to-head clinical analysis: ARISTOCORT versus ASMANEX HFA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARISTOCORT versus ASMANEX HFA.
ARISTOCORT vs ASMANEX HFA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Glucocorticoid receptor agonist; suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis; modulates gene expression and immune cell activity.
Mometasone furoate is a corticosteroid that exerts anti-inflammatory effects by inhibiting multiple inflammatory cell types and mediators, including eosinophils, mast cells, macrophages, and lymphocytes, and reducing the release of pro-inflammatory cytokines and chemokines.
Intramuscular: 40-80 mg every 2-4 weeks; Intra-articular: 5-40 mg depending on joint size; Intralesional: 2.5-25 mg; Oral: 4-12 mg/day divided every 6-12 hours.
2 inhalations (100 mcg each) twice daily orally, maximum 400 mcg/day.
None Documented
None Documented
Plasma: 1-2 hours (triamcinolone); tissue half-life 18-36 hours due to receptor binding and slow release from tissues.
The terminal elimination half-life of mometasone furoate following inhalation is approximately 25 hours (range 15–40 hours), reflecting slow absorption from the lungs and prolonged systemic clearance.
Renal (primarily as inactive metabolites); <5% unchanged. Biliary/fecal elimination minor.
Following oral inhalation, the absorbed fraction of mometasone furoate is extensively metabolized in the liver. Excretion is primarily via feces (approximately 74%) and urine (approximately 8%) as metabolites. Biliary excretion contributes to fecal elimination.
Category C
Category C
Corticosteroid
Corticosteroid, Inhaled